Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status [7]

Leukemia

Volumn 22, Issue 3, 2008, Pages 646-649

  Cortelezzi, A ^a,b   Gritti, G ^b   Del Papa, N ^c   Pasquini, M C ^a   Calori, R ^b   Gianelli, U ^a   Cortiana, M ^b   Parati, G ^d   Onida, F ^a,b   Sozzi, F ^b   Vener, C ^a   Bianchi, P ^b   Deliliers, G L ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BUSULFAN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; HYDROXYUREA; PLATELET DERIVED GROWTH FACTOR AB; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CARDIOPULMONARY INSUFFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMAN; LABORATORY TEST; LETTER; MALE; MYELOID METAPLASIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYMPTOM; SYSTOLIC BLOOD PRESSURE; THROMBOEMBOLISM;

EID: 40749161510     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404943     Document Type: Letter

References (9)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
2. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
3. Dingl D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120: 801-808.
4. Garcia-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 1999; 60: 130-135.
5. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
6. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al. Circulatirg endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007.
7. + and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 5688-5695.
8. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N et al Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003; 108: 889-895.
9. Del Papa N, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004; 50: 1296-1304.